Profile data is unavailable for this security.
About the company
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
- Revenue in USD (TTM)509.34m
- Net income in USD-207.04m
- Incorporated2000
- Employees1.45k
- LocationNovocure LtdNo. 4 The Forum, Grenville StreetSAINT HELIER JE2 4UFJerseyJEY
- Phone+44 1 534756700
- Websitehttps://www.novocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.24bn | 30.00 | -- | -- | -- | 1,399.14 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.25bn | 20.00 | -- | 13.22 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.25bn | 711.00 | 39.70 | 1.44 | 10.66 | 1.86 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.28bn | 58.00 | 24.57 | 1.79 | 14.20 | 9.77 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.30bn | 147.00 | -- | 3.55 | -- | 62.68 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.31bn | 267.00 | -- | -- | -- | 2.95 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Pharvaris NV | 0.00 | -108.03m | 1.32bn | 82.00 | -- | 3.12 | -- | -- | -2.70 | -2.70 | 0.00 | 7.87 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Novocure Ltd | 509.34m | -207.04m | 1.37bn | 1.45k | -- | 3.76 | -- | 2.69 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.37bn | 55.00 | -- | 2.09 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.38bn | 297.00 | 227.70 | 3.18 | 126.71 | 4.56 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.40bn | 642.00 | 81.03 | 3.15 | 18.14 | 2.87 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.40bn | 124.00 | -- | 2.11 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.41bn | 577.00 | -- | 2.53 | -- | 12.05 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Neumora Therapeutics Inc | 0.00 | -235.93m | 1.45bn | 124.00 | -- | 3.08 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Xencor Inc | 168.34m | -126.09m | 1.48bn | 280.00 | -- | 2.18 | -- | 8.76 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.49bn | 112.00 | -- | 4.38 | -- | 24.83 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Data as of May 02 2024. Currency figures normalised to Novocure Ltd's reporting currency: US Dollar USD
53.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 15.90m | 14.84% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 9.60m | 8.97% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 8.86m | 8.28% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.99m | 5.59% |
| Baillie Gifford & Co.as of 31 Dec 2023 | 4.84m | 4.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.86m | 3.61% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 3.28m | 3.06% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.13m | 1.99% |
| Two Sigma Advisers LPas of 31 Dec 2023 | 1.63m | 1.53% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.59m | 1.49% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
